{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:19:14Z","timestamp":1791357554985,"version":"4.3.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T00:00:00Z","timestamp":1475452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Forest Research Institute, Inc."},{"name":"Forest Research Institute, Inc"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jad-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jad.2016.09.037","type":"journal-article","created":{"date-parts":[[2016,10,15]],"date-time":"2016-10-15T11:00:53Z","timestamp":1476529253000},"page":"384-392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Long-term safety and tolerability of asenapine: A double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorder"],"prefix":"10.1016","volume":"207","author":[{"given":"Terence A.","family":"Ketter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Durgam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Landbloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mackle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maju","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2016.09.037_bib1","series-title":"4th ed, Text Revision.","article-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.jad.2016.09.037_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.jad.2016.09.037_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jad.2015.06.059","article-title":"Asenapine: efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder","volume":"190","author":"Landbloom","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2016.09.037_bib4","first-page":"757","article-title":"Impact of bipolar disorder in employed populations","volume":"14","author":"Laxman","year":"2008","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.jad.2016.09.037_bib5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1001\/jama.2013.65164","article-title":"Risk factors associated with suicide in current and former US military personnel","volume":"310","author":"LeardMann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2016.09.037_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1755-5949.2010.00200.x","article-title":"Asenapine: a review of acute and extension phase data in bipolar disorder","volume":"17","author":"McIntyre","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jad.2016.09.037_bib7","first-page":"28","article-title":"Tolerability Profiles of Atypical Antipsychotics in the Treatment of Bipolar Disorder","volume":"66","author":"McIntyre","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.037_bib8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0165-0327(14)70003-5","article-title":"The prevalence and burden of bipolar depression","volume":"169","author":"Miller","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2016.09.037_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jama.2013.13805","article-title":"The state of US health, 1990-2010: burden of diseases, injuries, and risk factors","volume":"310","author":"Murray","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2016.09.037_bib10","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/archpsyc.58.9.844","article-title":"Excess mortality in bipolar and unipolar disorder in Sweden","volume":"58","author":"\u00d6sby","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.037_bib11","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1176\/appi.ajp.160.7.1286","article-title":"Insurance expenditures on bipolar disorder: clinical and parity implications","volume":"160","author":"Peele","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.037_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/appi.ajp.163.2.217","article-title":"Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD)","volume":"163","author":"Perlis","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.037_bib13","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1176\/ajp.149.8.999","article-title":"Transduction of psychosocial stress into the neurobiology of recurrent affective disorder","volume":"149","author":"Post","year":"1992","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl","key":"10.1016\/j.jad.2016.09.037_bib14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1600-0447.1985.tb10510.x","article-title":"The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH","volume":"317","author":"Roy-Byrne","year":"1985","journal-title":"Acta Psychiat. Scand."},{"key":"10.1016\/j.jad.2016.09.037_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1055\/s-0030-1248313","article-title":"Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder","volume":"43","author":"Schoemaker","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jad.2016.09.037_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1477-7525-9-90","article-title":"Differences in demographic composition and in work, social, and functional limitations among the populations with unipolar depression and bipolar disorder: results from a nationally representative sample","volume":"9","author":"Shippee","year":"2011","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.jad.2016.09.037_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1399-5618.2005.00186.x","article-title":"Quality of life for patients with bipolar disorder: relationship with clinical and demographic variables","volume":"7","author":"Sierra","year":"2005","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2016.09.037_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jad.2014.09.003","article-title":"Risk factors for suicide in bipolar disorder: a systematic review","volume":"170","author":"da Silva Costa","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2016.09.037_bib19","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1176\/appi.ajp.160.12.2099","article-title":"The McLean-Harvard first-episode mania study: prediction of recovery and first recurrence","volume":"160","author":"Tohen","year":"2003","journal-title":"Am. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032716305997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032716305997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T12:54:08Z","timestamp":1536324848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032716305997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":19,"alternative-id":["S0165032716305997"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2016.09.037","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and tolerability of asenapine: A double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2016.09.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Allergan plc. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}